RecruitingPhase 2NCT00412594

Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

Phase II Study of 2-Chlorodeoxyadenosine (2CDA) Followed by Rituximab in Hairy Cell Leukemia

Sponsor

M.D. Anderson Cancer Center

Enrollment

150 participants

Start Date

Jun 10, 2004

Study Type

INTERVENTIONAL

Conditions

Hairy Cell Leukemia Recurrent Hairy Cell Leukemia

Summary

This phase II trial studies the side effects and how well cladribine and rituximab work in treating patients with hairy cell leukemia. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as rituximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cladribine together with rituximab may kill more cancer cells.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a combination of two drugs — cladribine and rituximab — to treat hairy cell leukemia, a rare and slow-growing type of blood cancer, to see if combining them works better than using cladribine alone. **You may be eligible if...** - You have been diagnosed with hairy cell leukemia - You are 18 years of age or older - Your blood counts and organ function are adequate for treatment - You have not previously been treated with cladribine, or your disease has come back after prior treatment **You may NOT be eligible if...** - You have a serious active infection - Your heart, liver, or kidney function is significantly impaired - You are pregnant or breastfeeding - You have had a severe reaction to rituximab or similar drugs in the past Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.